SPONSORSHIP

Caldolor® (ibuprofen) Injection is indicated in adults and children 3 months of age and older for the management of mild to moderate pain, the management of moderate to severe pain as an adjunct to opioid analgesics, and for the reduction of fever. Caldolor is the first FDA-approved intravenous therapy for both fever and pain.

Masimo, a Danaher company, is a specialty diagnostics solutions innovator of AI-enabled pulse oximetry and other patient monitoring solutions designed to empower clinicians to transform patient care. Masimo’s industry-leading technologies include parameters, sensors, and patient monitors, alongside connectivity and telehealth solutions. Masimo’s breakthrough SET® pulse oximetry and rainbow® Pulse CO-Oximetry parameters allow accurate, reliable noninvasive and continuous monitoring in challenging conditions like motion and low perfusion, across all skin tones, and of blood constituents that previously could only be measured invasively, like total hemoglobin (SpHb®). Additional modalities, such as LiDCO® hemodynamic monitoring, SedLine® and O3® brain monitoring, and NomoLine® capnography, offer clinicians ever more comprehensive, insightful data to support informed care decisions. Powered by the Masimo Hospital Automation™ platform, Masimo solutions facilitate true curb-to-curb continuous patient monitoring, helping clinicians improve care delivery, workflows, and patient outcomes. Key platform components include the Root® monitoring hub, the versatile, patient-worn Radius VSM® vital signs monitor, and the Patient SafetyNet™ supplemental monitoring and clinician notification system with Halo™ algorithmic patient assessment scoring. And with the Masimo SafetyNet® remote patient management and telehealth platform, alongside such innovations as the Masimo W1® medical watch, Masimo is advancing the forefront of hospital-to-home and hospital-at-home care.

LXO is a global specialty pharmaceutical company that is focused on acquiring prescription medicines across a broad range of therapeutic areas in international markets. The company focuses its resources on acquiring and optimizing established medicines.

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and conditions. The company has approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and research programs in these areas. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, primary membranous nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes and myotonic dystrophy type 1.

Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America and the Middle East. Vertex is consistently recognized as one of the industry's top places to work, including 16 consecutive years on Science magazine's Top Employers list and one of Fortune’s 100 Best Companies to Work For. For company updates and to learn more about Vertex's history of innovation, visit www.vrtx.com or follow us on LinkedIn, Facebook, Instagram, YouTube and X.

Abbott develops innovative and science-based nutrition products that provide nutritional support for patient growth, recovery, and sustainability.

Axolo Health is an innovative medical technology company focused on transforming patient care through immersive virtual reality (VR) and Targeted Brain Rehabilitation (TBR). Its technology offers a noninvasive, patient-centered approach designed to support rehabilitation, enhance patient experiences, and improve clinical outcomes.

BD is dedicated to advancing the world of health with intelligent innovations for advanced patient monitoring. Our AI-powered hemodynamic monitoring solutions provide real-time data and insights that enhance decision-making across a range of clinical situations. Through ongoing collaboration with clinicians, BD develops smart hemodynamic management solutions supported by robust clinical education that help healthcare professionals stay ahead of critical moments.

Headquartered in Lachen, Switzerland, Octapharma is one of the largest human protein manufacturers in the world, developing and producing human proteins from human plasma and human cell lines. Octapharma employs nearly 12,000 employees worldwide to support the treatment of patients in 118 countries with products across three therapeutic areas: Immunotherapy, Hematology and Critical Care. Octapharma has seven R&D sites and five state-of-the-art manufacturing facilities in Austria, France, Germany and Sweden, and operates more than 190 plasma donation centers across Europe and the US. Octapharma has 40 years of experience in patient care.

Pacira BioSciences, Inc. is the industry leader in its commitment to non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. To learn more about Pacira, including the corporate mission to reduce overreliance on opioids, visit www.pacira.com.